THW (Tekla World Healthcare Fund) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


THW Tekla World Healthcare Fund THW
57 GF Score
Price $13.49
GF Value $19.36
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Tekla World Healthcare Fund Research & Development?

Tekla World Healthcare Fund THW -1.32% 57 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates THW with a GF Score™ of 57/100 and a GF Value™ of $19.36 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tekla World Healthcare Fund's Research & Development for the six months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Tekla World Healthcare Fund  (NYSE:THW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tekla World Healthcare Fund Research & Development Related Terms

Tekla World Healthcare Fund Research & Development Historical Data

* Premium members only.

The historical data trend for Tekla World Healthcare Fund's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tekla World Healthcare Fund Research & Development Chart

Tekla World Healthcare Fund Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tekla World Healthcare Fund Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
THW
57GF Score
Tekla World Healthcare Fund THW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tekla World Healthcare Fund Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Tekla World Healthcare Fund (THW) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Tekla World Healthcare Fund and its competitors.
Is Tekla World Healthcare Fund's Research & Development too high?
Tekla World Healthcare Fund's current Research & Development is $0.00 Mil. Overall, Tekla World Healthcare Fund has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tekla World Healthcare Fund's Research & Development compare to MSIF and IQI?
Tekla World Healthcare Fund's Research & Development of $0.00 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tekla World Healthcare Fund and its competitors. Tekla World Healthcare Fund's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tekla World Healthcare Fund stock overvalued right now?
Based on GuruFocus' analysis, Tekla World Healthcare Fund (THW) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.36, compared to a current price of $13.49 — trading 30.3% below its estimated fair value. The current Research & Development is $0.00 Mil. Tekla World Healthcare Fund's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tekla World Healthcare Fund (THW), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tekla World Healthcare Fund (THW) Overvalued in 2026?

Based on GuruFocus' analysis, Tekla World Healthcare Fund stock appears to be undervalued. The current stock price of $13.49 is trading 30.3% below its estimated GF Value™ of $19.36. GuruFocus considers Tekla World Healthcare Fund to be Significantly Undervalued.

Key valuation signals for THW:

  • Research & Development: $0.00 Mil
  • GF Value™: $19.36 vs. price of $13.49 (30.3% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the THW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tekla World Healthcare Fund Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.
57GF Score

Get the complete analysis for THW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.49
Price
$19.36
GF Value